MaxRS Ventures (AQSE:MAX) Balance Sheet Cash And Cash Equivalents : £0.02 Mil (As of Oct. 2023)

View and export this data going back to 2019. Start your Free Trial

What is MaxRS Ventures Balance Sheet Cash And Cash Equivalents?

MaxRS Ventures's quarterly cash and cash equivalents declined from Oct. 2021 (£0.88 Mil) to Oct. 2022 (£0.41 Mil) and declined from Oct. 2022 (£0.41 Mil) to Oct. 2023 (£0.02 Mil).

MaxRS Ventures's annual cash and cash equivalents declined from Oct. 2021 (£0.88 Mil) to Oct. 2022 (£0.41 Mil) and declined from Oct. 2022 (£0.41 Mil) to Oct. 2023 (£0.02 Mil).

MaxRS Ventures Balance Sheet Cash And Cash Equivalents Historical Data

The historical data trend for MaxRS Ventures's Balance Sheet Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxRS Ventures Balance Sheet Cash And Cash Equivalents Chart

MaxRS Ventures Annual Data

Trend

Oct19

Oct20

Oct21

Oct22

Oct23

Balance Sheet Cash And Cash Equivalents

0.50

1.46

0.88

0.41

0.02

MaxRS Ventures Semi-Annual Data
	Oct19	Oct20	Oct21	Oct22	Oct23
Balance Sheet Cash And Cash Equivalents	0.50	1.46	0.88	0.41	0.02

MaxRS Ventures Balance Sheet Cash And Cash Equivalents Calculation

Cash and cash equivalents on banks book.

MaxRS Ventures (AQSE:MAX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » MaxRS Ventures Plc (AQSE:MAX) » Definitions » Balance Sheet Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 Sloane Avenue, London, GBR, SW3 3DD

Website

https://www.maxrets.com

MaxRS Ventures Plc is an investment company that seeks to maximize returns for shareholders predominantly through capital appreciation, by investing in or acquiring distressed or out-of-favor assets that the Board believes have become undervalued or which may benefit from consolidation as a result of the current challenging economic and geopolitical landscape. The company's investment is currently focussed on four sectors comprising life sciences, fintech businesses and assets that use fintech, impact investing (environmental and renewables), and retail.